Background: Bullous pemphigoid (BP) is a rare, autoantibody-mediated bullous disease which can have significant morbidity and mortality. Bullous pemphigoid is commonly treated with high doses of systemic corticosteroids and often, immunosuppressive medications on a prolonged basis.
Study Design: Retrospective chart analysis Methods: Comparative evaluation of therapeutic outcomes and relative frequency of adverse effects in 13 patients diagnosed with bullous pemphigoid.
Results: Complete response to maintenance-phase of therapy was established in 38% (5/13) of all BP patients and sustained for 6-14 months (median 10 months). Partial response was achieved in 46% (6/l3) patients and sustained for 5-36 months (median 8 months).
Conclusion: Overall, the majority of patient responded well to a combination of systemic corticosteroids, tetracycline antibiotics, anti-inflammatories, and/or topical corticosteroids with a significant reduction in disease activity.
Files are restricted to Pacific University. Sign in to view.